

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/536,772	05/26/2005	Jianren Gu	186691/US	4584
52835 7590 10/09/2007 HAMRE, SCHUMANN, MUELLER & LARSON, P.C. P.O. BOX 2902			EXAMINER	
			REDDIG, PETER J	
MINNEAPOLI	S, MN 55402-0902		ART UNIT PAPER NUMBER	
			1642	
			MAIL DATE	DELIVERY MODE
			10/09/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application No.	Applicant(s)		
Office Action Summary		10/536,772	GU ET AL.		
		Examiner	Art Unit .		
		Peter J. Reddig	1642		
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY WHICHEVER IS LONGER, FR - Extensions of time may be available under after SIX (6) MONTHS from the mailing of If NO period for reply is specified above, Failure to reply within the set or extended	OM THE MAILING DA er the provisions of 37 CFR 1.13 ate of this communication. the maximum statutory period w period for reply will, by statute, in three months after the mailing	'IS SET TO EXPIRE 3 MONTH( ATE OF THIS COMMUNICATION 6(a). In no event, however, may a reply be tim ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE date of this communication, even if timely filed	N. sely filed the mailing date of this communication. D (35 U.S.C. § 133).		
Status	•				
,	2b)⊡ This n condition for allowan	<i>ly 2007</i> . action is non-final. ace except for formal matters, pro <i>x parte Quayle</i> , 1935 C.D. 11, 45			
Disposition of Claims					
4) ⊠ Claim(s) <u>1,11 and 12</u> is/a 4a) Of the above claim(s) 5) □ Claim(s) is/are all 6) ⊠ Claim(s) <u>1</u> is/are rejected 7) □ Claim(s) is/are ob 8) □ Claim(s) are subjected	11 and 12 is/are withoused.  I. jected to.	drawn from consideration.			
Application Papers					
Applicant may not request t Replacement drawing shee	is/are: a) acce hat any objection to the o t(s) including the correcti	epted or b) objected to by the formula of the formula of the formula of the drawing on is required if the drawing (s) is objection. Note the attached Office	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).		
Priority under 35 U.S.C. § 119					
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No.</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>					
Attachment(s)					
Notice of References Cited (PTO-89     Notice of Draftsperson's Patent Drav     Information Disclosure Statement(s)     Paper No(s)/Mail Date	ving Review (PTO-948)	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ate		

Application/Control Number: 10/536,772 Page 2

Art Unit: 1642

## **DETAILED ACTION**

1. The Amendment filed July 17, 2007 in response to the Office Action of April 17, 2007 is acknowledged and has been entered. Previously pending claims 2-10 have been cancelled, claim 1 has been amended, and new claims 11 and 12, drawn to the subject matter of a previously not elected invention have been added.

- 2. Since applicant has received an action on the merits for the originally presented invention, this invention has been constructively elected by original presentation for prosecution on the merits. Accordingly, claims 11 and 12 are withdrawn from consideration as being directed to a non-elected invention. See 37 C.F.R., 1.142(b) and M.P.E.P., 821.03.
- 3. Claim 1 is currently under consideration.
- 4. The following rejections/objections are being maintained:

## Specification

5. Applicants argue that the specification is objected to for improper disclosure of amino acid sequences without respective sequence identifiers. To comply with 37 CFR § 1.821-1.825, Applicants respectfully submit a computer readable form (CRF) of the sequence listing, a substitute paper copy of the sequence listing, as well as an amendment directing its entry into the specification and a statement as required. The substitute sequence listing has been mailed to Mailstop Sequence along with a copy of the Notice to Comply, as required by the Office Action. With further particularity, SEQ ID NOs: 14-18 have been added to the sequence listing, which respectively correspond to sequences for CT120, CT120B, CT 120-like, mCT120-like 1 and mCT120-like 2, and which are provided in Applicants' specification, for example at page 15, lines 28-33 and in Figure 1. Applicants respectfully submit that the specification is in proper form.

Art Unit: 1642

Applicants' arguments have been carefully considered, but have not been found persuasive because the compact disk containing the sequences is defective as stated in the notice mailed August 8, 2007. Additionally, reference to the SEQ ID NO: numbers needs to be added to the brief description of Figure 1.

## **Priority**

6. Applicants argue that this Application enjoys the benefit of priority having the date

November 27, 2002 for the reasons herein. As suggested by the Examiner, Applicants enclose herewith the English translations of the priority documents PCT/CN03/00845 and

CN02150730.9. Applicants respectfully submit that the English translation of the international application PCT/CN03/00845 corresponds to the present application as filed on May 25, 2005.

Thus, Applicants believe that this translation should be identical with the present application. As to the English translation of CN02150730.9, Applicants respectfully submit the translation is substantially identical to PCT/CN03/00845, where both priority applications include the subject matter disclosed and claimed in the present application. In fact, the subject matter claimed is supported throughout the disclosures of these priority documents. For example, the drawings of PCT/CN03/00845 and CN02150730.9, which also are the same as that of the present application, disclose the features claimed. For at least these reasons, Applicants believe that they are entitled to enjoy the benefit of priority of PCT/CN03/00845 as well as CN02150730.9, which was filed on November 27, 2002.

Applicants' arguments have been carefully considered and have been found persuasive in part. The priority date will be reset to October 8, 2003 based on the filing date of the international application PCT/CN03/00845. However, in regard to the translation of

Art Unit: 1642

CN02150730.9, a translation must be filed together with a statement that the translation of the certified copy is accurate, see MPEP 201.15, and no such statement is present. Submission of a statement that the translation of the certified copy is accurate would obviate this objection.

## Claim Rejections - 35 USC § 102

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

7. Claim 1 remains rejected under 35 USC 102(b) as being anticipated by He et al. (Biochem. Biophys. Res. Com., September 27, 2002, 297:528-536, IDS) for the reasons previously set forth in section 11, pages 18-19 of the Office Action of April 17, 2007.

Applicants argue that He et al. does not constitute prior art as alleged in the Office Action, because the present application is entitled to enjoy the priority of CN 02150730.9, which was filed on November 27, 2002.

Applicants' arguments have been carefully considered, but have not been found persuasive because, as set forth above, the priority is currently October 8, 2003 for the instantly claimed invention. It is noted that even if Applicants were granted priority to the foreign application, CN02150730.9, the application would remain rejected under 35 USC 102(b). The right to rely on the foreign filing extends to overcoming the effects of intervening references or uses, but there are certain restrictions. For example, the 1 year bar of 35 U.S.C. 102(b) dates from the U.S. filing date and not from the foreign filing date; thus if an invention was described in a printed publication, or was in public use in this country, in November 1981, a foreign application filed in January 1982, and a U.S. application filed in December 1982, granting a patent on the U.S. application is barred by the printed publication or public use occurring more than one year prior to its actual filing in the United States, see MPEP 201.13 (III).

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

8. Claim 1 remains rejected under 35 USC 102, now 35 USC 102(a), in view of the change in priority date, as being anticipated by He et al. (Chinese Journal of Cancer, February, 2003, 22:113-8) for the reasons previously set forth in section 12, pages 19-20 of the Office Action of April 17, 2007.

Applicants argue that He et al. does not constitute prior art as alleged in the Office Action, because the present application is entitled to enjoy the priority of CN 02150730.9, which was filed on November 27, 2002.

Applicants' arguments have been carefully considered, but have not been found persuasive because, as set forth above, the priority is currently October 8, 2003 for the instantly claimed invention. Submission of a statement that the translation of the certified copy of CN 02150730.9 is accurate would obviate this rejection.

Applicant's arguments have not been found persuasive and the rejection is maintained.

- 9. All other objections and rejections recited in the Office Action of April 17, 2007are withdrawn.
- 10. No claims allowed.
- 11. This action is a **final rejection** and is intended to close the prosecution of this application. Applicant's reply under 37 CFR 1.113 to this action is limited either to an appeal to the Board of Patent Appeals and Interferences or to an amendment complying with the requirements set forth below.

If applicant should desire to appeal any rejection made by the examiner, a Notice of Appeal must be filed within the period for reply identifying the rejected claim or claims appealed. The Notice of Appeal must be accompanied by the required appeal fee.

Application/Control Number: 10/536,772

Art Unit: 1642

If applicant should desire to file an amendment, entry of a proposed amendment after final rejection cannot be made as a matter of right unless it merely cancels claims or complies with a formal requirement made earlier. Amendments touching the merits of the application which otherwise might not be proper may be admitted upon a showing a good and sufficient reasons why they are necessary and why they were not presented earlier.

A reply under 37 CFR 1.113 to a final rejection must include the appeal form, or cancellation of, each rejected claim. The filing of an amendment after final rejection, whether or not it is entered, does not stop the running of the statutory period for reply to the final rejection unless the examiner holds the claims to be in condition for allowance. Accordingly, if a Notice of Appeal has not been filed properly within the period for reply, or any extension of this period obtained under either 37 CFR 1.136(a) or (b), the application will become abandoned.

12. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 C.F.R. 1.136(a).

A SHORTENED STATUTORY PERIOD FOR RESPONSE TO THIS FINAL ACTION IS SET TO EXPIRE THREE MONTHS FROM THE DATE OF THIS ACTION. IN THE EVENT A FIRST RESPONSE IS FILED WITHIN TWO MONTHS OF THE MAILING DATE OF THIS FINAL ACTION AND THE ADVISORY ACTION IS NOT MAILED UNTIL AFTER THE END OF THE THREE-MONTH SHORTENED STATUTORY PERIOD, THEN THE SHORTENED STATUTORY PERIOD WILL EXPIRE ON THE DATE THE ADVISORY ACTION IS MAILED, AND ANY EXTENSION FEE PURSUANT TO 37 C.F.R. 1.136(a) WILL BE CALCULATED FROM THE MAILING DATE OF THE ADVISORY ACTION. IN NO EVENT WILL THE STATUTORY PERIOD FOR RESPONSE EXPIRE LATER THAN SIX MONTHS FROM THE DATE OF THIS FINAL ACTION.

13. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Peter J. Reddig whose telephone number is (571) 272-9031. The examiner can normally be reached on M-F 8:30 a.m.-5:00 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Shanon Foley can be reached on (571) 272-0890. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1642

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Peter J. Reddig Examiner Art Unit 1642 SUSAN UNGAR, PH.D PRIMARY EXAMINER

PJR